GLI2 and chronic myelogenous leukemia, BCR-ABL1 positive: Similar results were also observed using PF-04449913, an orally bioavailable small molecule Smo antagonist, and the TKI Dasatinib, which reduced CML LSC burden by Gli2 inhibition [108], suggesting that targeting both tyrosine kinase and Hh activity might be an effective combination therapy in CML patients [105].